MGAT5 and carcinoma: Our results further showed that tumors derived from Mgat5 KO mice presented a tendency for lower levels of the immune checkpoint inhibitor PD-L1 molecules in the carcinoma stage (Figure S4G), which is in line with the activating and non-immunosuppressed phenotype of T cells in KO mice.